CXA-10

Generic Name: CXA-10

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₃₃NO_₄

CAS Number: 875685-46-4

Unique Ingredient Identifier: 1N19AGY57Y

Background: CXA-10 is under investigation in clinical trial NCT03422510 (FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)).

Clinical Trials

Oral CXA-10 in Pulmonary Arterial Hypertension

Phase 2

Terminated

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: CXA-10

First Posted Date: 2019-10-14

Last Posted Date: 2022-01-12

Lead Sponsor: Gladwin, Mark, MD

Target Recruit Count: 1

Registration Number: NCT04125745

Locations: 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

CXA-10 Study in Subjects With Pulmonary Arterial Hypertension

Phase 2

Terminated

Conditions: PAH

Interventions: Drug: CXA-10

First Posted Date: 2019-08-12

Last Posted Date: 2020-08-26

Lead Sponsor: Complexa, Inc.

Target Recruit Count: 33

Registration Number: NCT04053543

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 34 locations

Anti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma

Phase 2

Recruiting

Conditions: Obesity
Asthma

Interventions: Drug: Matching Placebo
Drug: CXA-10

First Posted Date: 2018-12-03

Last Posted Date: 2024-03-04

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 60

Registration Number: NCT03762395

Locations: 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Anti-Inflammatory Lipid Mediators in Asthma

Phase 2

Withdrawn

Conditions: Asthma

Interventions: Drug: CXA-10
Drug: Placebo

First Posted Date: 2018-09-21

Last Posted Date: 2018-09-21

Lead Sponsor: Sally E. Wenzel MD

Registration Number: NCT03680976

Locations: 🇺🇸
The University of Pittsburgh Asthma Institute at UPMC, Pittsburgh, Pennsylvania, United States

PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)

Phase 2

Terminated

Conditions: PAH

Interventions: Drug: 75mg CXA-10
Other: Placebo
Drug: 150mg CXA-10

First Posted Date: 2018-02-28

Last Posted Date: 2020-08-10

Lead Sponsor: Complexa, Inc.

Target Recruit Count: 69

Registration Number: NCT03449524

Locations: 🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
🇺🇸
Washington Hospital (Medstar), Washington, District of Columbia, United States

and more 43 locations

FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)

Phase 2

Completed

Conditions: Primary Focal Segmental Glomerulosclerosis

Interventions: Drug: CXA-10

First Posted Date: 2018-02-05

Last Posted Date: 2020-08-03

Lead Sponsor: Complexa, Inc.

Target Recruit Count: 33

Registration Number: NCT03422510

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Northwest Louisiana Nephrology, Shreveport, Louisiana, United States
🇺🇸
St. Clair Nephrology Research, Roseville, Michigan, United States

and more 21 locations

A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males

Phase 1

Completed

Conditions: Acute Kidney Injury

Interventions: Drug: CXA-10
Drug: pravastatin
Drug: Vytorin® (combination of simvastatin and ezetimibe)

First Posted Date: 2015-09-11

Last Posted Date: 2016-05-03

Lead Sponsor: Complexa, Inc.

Target Recruit Count: 10

Registration Number: NCT02547402

Locations: 🇺🇸
Jasper Clinical Research & Development, Inc., Kalamazoo, Michigan, United States

PK and PD of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects

Phase 1

Completed

Conditions: Acute Kidney Injury

Interventions: Other: CXA-10 placebo
Drug: CXA-10

First Posted Date: 2015-06-02

Last Posted Date: 2016-05-03

Lead Sponsor: Complexa, Inc.

Target Recruit Count: 43

Registration Number: NCT02460146

Locations: 🇺🇸
Jasper Clinical Research & Development, Inc., Kalamazoo, Michigan, United States

Oral CXA-10 Study in Healthy Volunteers

Phase 1

Completed

Conditions: Chronic Kidney Injury

Interventions: Drug: CXA-10 placebo
Drug: CXA-10

First Posted Date: 2014-12-09

Last Posted Date: 2016-05-03

Lead Sponsor: Complexa, Inc.

Target Recruit Count: 40

Registration Number: NCT02313064

Locations: 🇺🇸
Jasper Clinical Research & Development, Inc., Kalamazoo, Michigan, United States

Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury

Phase 1

Completed

Conditions: Acute Kidney Injury (Nontraumatic)

Interventions: Drug: CXA-10

First Posted Date: 2014-09-25

Last Posted Date: 2018-02-01

Lead Sponsor: Complexa, Inc.

Target Recruit Count: 12

Registration Number: NCT02248051

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸
Jasper Clinical Research & Development, Inc., Kalamazoo, Michigan, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy